Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye

2013 ASCO Annual Meeting

30 May - 3 Jun 2013

Published: 1 Jun 2013

Views: 5070

Rating:

Save

Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Richard D. Carvajal presents the final analysis of data from a phase II cross-over study in patients with metastatic melanoma of the eye during a press conference at the 2013 ASCO Annual Meeting in Chicago.

The study found that selumetinib resulted in tumour shrinkage in half of all patients treated and a duration of disease control more than twice that achieved with temozolomide.

Visit ecancerNews to read more

Related Videos

Head and Neck Cancers

Dr Vijay Patil - Hinduja Hospital & Medical Research Centre, Mumbai

Head and Neck Cancers ( Dr Vijay Patil - Hinduja Hospital & Medical Research Centre, Mumbai )

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

Updates in melanoma and skin cancers

Dr Sanjiv Agarwala - St. Luke’s Cancer Center, Philadelphia, USA

Updates in melanoma and skin cancers ( Dr Sanjiv Agarwala - St. Luke’s Cancer Center, Philadelphia, USA )

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

2L triple metronomic chemo shows more efficacy in comparison to systemic...

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital...

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma...

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )

More from ecancer